Trial Profile
Prospective Study of Complete Remissions Observed With Sunitinib in Patients With Metastatic Renal Cell Carcinoma mRCC)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 Nov 2023
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms APERCU
- Sponsors Pfizer
- 14 Feb 2022 Status changed from recruiting to completed.
- 29 Apr 2020 Planned End Date changed from 15 Apr 2020 to 1 Dec 2021.
- 29 Apr 2020 Planned primary completion date changed from 15 Apr 2020 to 1 Dec 2021.